Results 51 to 60 of about 4,323 (176)

PDGFRα+DPP4+ Fibroblasts‐Macrophage Crosstalk Induces Orbital Fibrosis in Treatment‐Resistant Thyroid Eye Disease via the GAS6‐AXL Pathway

Advanced Science, Volume 12, Issue 45, December 4, 2025.
This study elucidates macrophage‐induced orbital fibrosis in TED via the GAS6‐AXL pathway, a treatment‐resistant disorder lacking non‐surgical therapies. Using a novel patient cell‐derived orthotopic animal model of orbital fibrosis for TED, we repurpose an existing fibrosis therapy, addressing the absence of stable models and offering a potential ...
Lu Cheng, Jinwei Cheng, Guiling Liang, Xiaorui Wang, Yanwen Ge, Jiapei Liu, Luwei Cai, Hui Ying, Fenfen Wang, Jing Hu, Yufan Wang, Philipp E. Scherer, Ben Zhou, Mengle Shao, Fang Zhang   +14 more
wiley   +1 more source

Graves Orbitopathy [PDF]

Journal of Osteopathic Medicine, 2020
Stefano, Natali, Paul, Shogan
openaire   +2 more sources

Application of Machine Learning to Discriminate Photoreceptor Cell Species in Xenotransplanted Chimeric Retinas

Clinical and Translational Science, Volume 18, Issue 12, December 2025.
ABSTRACT Photoreceptor transplantation is being studied to restore visual function in retinal diseases causing blindness, including age‐related macular degeneration, hereditary eye diseases, and traumatic retinopathy. Preclinical studies often involve delivering exogenous human photoreceptor cells into animal models' retinas.
Kang V. Li, Annabelle Pan, Ying V. Liu, Bani Antonio‐Aguirre, Joyce Wang, McKaily Adams, Christina McNerney, Sai Bo Bo Tun, Kenneth Jimenez, Yuchen Lu, Zhuolin Li, Minda McNally, Veluchamy A. Barathi, Robert J. Johnston Jr., Mandeep S. Singh   +14 more
wiley   +1 more source

Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab

European Thyroid Journal
Introduction: Secondary thyroid autoimmunity, especially Graves’ disease (GD), frequently develops in patients with multiple sclerosis (MS) following alemtuzumab treatment (ALTZ; anti-CD52). Thyroid eye disease (TED) can also develop, and rituximab (RTX;
Ilaria Muller, Sara Maioli, Mirco Armenti, Laura Porcaro, Nicola Currò, Elisabetta Iofrida, Lorenzo Pignataro, Jacopo Manso, Caterina Mian, Jens Geginat, Mario Salvi   +10 more
doaj   +1 more source

Clinical assessment of patients with Graves' orbitopathy [PDF]

Medicinski Glasnik Specijalne Bolnice za Bolesti Štitaste Žlezde i Bolesti Metabolizma "Zlatibor", 2011
Clinical examination is the basis of a good assessment of a patient with Graves' orbitopathy. This study gives recommendations of the European orbitopathy group related to the activity and severity of the disease. The activity of the disease is estimated
Nedeljković-Beleslin Biljana
doaj   +1 more source

Glymphatic System Dysfunction in Thyroid‐Associated Ophthalmopathy: A Multimodal MRI Study

CNS Neuroscience &Therapeutics, Volume 31, Issue 11, November 2025.
TAO patients exhibit impaired glymphatic function, with reduced DTI‐ALPS indices and gBOLD‐CSF coupling, but unchanged choroid plexus volume. These alterations correlate with neuropsychological symptoms and sleep disturbances. Restoring glymphatic activity may offer a therapeutic approach to enhance patient outcomes.
Lijie Zhang, Jiaqi Yao, Yiming Qi, Yongheng Luo, Jun Liu   +4 more
wiley   +1 more source

Upper eyelid retraction disclosed after edrophonium chloride administration in a patient with Graves' orbitopathy and myasthenia gravis

Clinical Ophthalmology, 2012
Hyera Kang,1,2 Yasuhiro Takahashi,1 Masayoshi Iwaki,1 Shinichi Asamura,3 Hirohiko Kakizaki,11Department of Ophthalmology, Aichi Medical University, Nagakute, Aichi, Japan; 2Department of Ophthalmology, Presbyterian Medical Center, Jeonju, Korea ...
Kang H, Takahashi Y, Iwaki M, Asamura S, Kakizaki H   +4 more
doaj  

Long‐term test and retest reliability of clinical vergence testing

Ophthalmic and Physiological Optics, Volume 45, Issue 7, Page 1630-1641, November 2025.
Abstract Purpose To establish long‐term reliability measures for vergence testing in a control population of adolescents. Methods Healthy participants between 12 and 17.5 years with normal binocular vision were recruited from 10 clinical sites. Cover test, near point of convergence (NPC), positive and negative fusional vergences, vergence facility (12∆
Mitchell Scheiman, Aparna Raghuram, Christina Master, Matthew L. Robich, Andrew Toole, Erica R. Shelton, Gayathri Srinivasan, Sophia Marusic, Siva Meiyeppen, Lisa A. Jordan, Tawna L. Roberts, EPICC Study Group, Tawna L. Roberts, Lisa A Jordan, Kristine N. Dalton, Gerald A. Grant, Yaping Joyce Liao, Jason Porter, Laura K. Purcell, Mitchell Scheiman, Mark A. Swanson, Suresh Viswanathan, Lisa A Jordan, Loraine T. Sinnott, Matthew L. Robich, Kimberly J. Shaw, Jill A. Myers, Stacey S. Choi, Jason Porter, Nimesh Patel, Chris Koutures, Jennifer Platt, Aparna Raghuram, Michael O’Brien, Neerali Vyas, Emily Wiecek, Sophia Marusic, Debora Ghosh, Carissa Wu, Christina Master, Lindsey Calandra, Katherine Easby, Anne Mozel, Olivia Podolak, Kathryn Rownd, Melissa Godfrey, Ian McGinnis, Colleen Ford, Kelsy Stenger, Karlie Pollock, Kaitlyn Housel, Angela Chen, Silvia Han, Kristine Huang, Susan M. Parker, Jillian Youngerman, Surbhi Bansal, Natalie Breau, Judith Wu, Allegra Burgher, Cristina Llerena Law, Alessandra Posey, Amar Sayani, Lailah Issac, Ryan Bennett, Katherine Green, Ahmed Riaz, Mitchell Scheiman, Siva Meiyeppen, Tawna Roberts, Gerald Grant, Emily Kraus, Shannon Beres, Heather Moss, Anna Wan, Kristin Slinger, Joellen Leonen, Amber Hu, Gayathri Srinivasan, Christabel Baah, Erin Moix Grieb, Caitlyn Lew, Tyler Vandiver, Kylie Clewes, Surbhi Bansal, Angela Lumba‐Brown, Arvind Balaji, Suresh Viswanathan, Patricia A. Modica, Ashwin Badrinath Pothiadia‐Irungovel, Matthew Vaughn, Catherine McDaniel, Ann Morrison, Douglas Widmer, Michelle Buckland, Erica Shelton, Andrew J. Toole, Nancy Stevens, Mark W. Swanson, Sara Gould, Jenifer Montejo, Laura Ferrill, Erin Swanson‐Kimani, Katherine K. Weise, Zenia Cardona, Kristine N. Dalton, Laura K. Purcell, Tammy Labreche, Julie Shalhoub, Dania Abuleil   +109 more
wiley   +1 more source

Ten Year Outcome of Anti‐Thyroid Drug Treatment for First Episode Graves' Thyrotoxicosis: The Predictive Importance of TRAb

Clinical Endocrinology, Volume 103, Issue 4, Page 612-618, October 2025.
ABSTRACT Objective To establish the risk and time course of recurrent thyrotoxicosis following withdrawal of anti‐thyroid drugs (ATD) and risk factors for recurrence. Design Single‐centre retrospective study. Methods Two hundred and ninety people with a first episode of Graves' thyrotoxicosis, who completed a course of ATD, were included.
Nyo Nyo Z. Tun, Nicola N. Zammitt, Mark W. J. Strachan, Jonathan R. Seckl, Fraser W. Gibb   +4 more
wiley   +1 more source

Patterns of Teprotumumab‐Induced Hearing Dysfunction: A Systematic Review

Otolaryngology–Head and Neck Surgery, Volume 173, Issue 3, Page 539-545, September 2025.
Abstract Objective Hearing loss has been reported after administration of the monoclonal antibody teprotumumab. The purpose of this study was to review available evidence regarding the patterns of teprotumumab‐related ototoxicity. Data Sources PubMed, EMBASE, and Cochrane Library.
Kevin Wong, Priya Arya, Yansy Salmeron, Douglas C. Bigelow, Michael J. Ruckenstein, Shubhasree Banerjee, Madhura Tamhankar, Jason A. Brant, Tiffany P. Hwa   +8 more
wiley   +1 more source